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http:WHAT THIS PAPER ADDS
This study aims to investigate the role of the novel biomarker galectin-3 in carotid vulnerability in patients with
high grade carotid stenosis. Galectin-3 may help identifying carotid plaques prone to rupture and cerebral
embolization. This study aims also to investigate the impact of statin therapy on galectin-3 levels. This rela-
tionship may provide additional information regarding the mechanism by which statins induce carotid plaque
stability.Objectives: Galectin-3, a member of galectines, a family of b-galactoside-speciﬁc lectins, has been reported to
propagate vascular inﬂammation. The role of galectin-3 in carotid atherosclerosis is controversial. The aim of this
study was to investigate the relationship of galectin-3 with plaque vulnerability in patients with high grade
carotid stenosis.
Methods: This was a cross sectional study of patients undergoing carotid endarterectomy (CEA). Carotid plaques
obtained from 78 consecutive patients (40 symptomatic [SG], 38 asymptomatic [AG]) undergoing CEA were
histologically analyzed for galectin-3, macrophages (CD68) and laminin. Pre-operatively the biochemical proﬁle
and plaque echogenicity (gray-scale median, GSM) score were determined.
Results: There were no signiﬁcant differences in clinical and demographic parameters between SG and AG
(p > .05). The SG had a lower GSM score (44.21  18.24 vs. 68.79  28.79, p < .001) and a smaller positive
stained area for galectin-3 (4.89  1.60% vs. 12.01  5.91%, p < .001) and laminin (0.88  0.71% vs.
3.46  2.12%, p < .001) than the AG. On the other hand, intra-plaque macrophage content was increased in SG
(p < .001). For the whole cohort, symptomatic status was independently associated with intra-plaque contents
of both galectin-3 (OR ¼ 0.634, p < .001), and GSM score (OR ¼ 0.750, p < .001). Notably, patients on long term
statin treatment had elevated galectin-3 and lowered macrophage intra-plaque concentrations compared with
those on short term treatment (p < .05).
Conclusions: A low galectin-3 intra-plaque concentration seems to correlate with clinically and ultrasonically
deﬁned unstable human carotid plaques. Long term statin treatment may induce increase of intra-plaque
galectin-3 concentration mediating plaque stabilization.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Stroke is one of the leading causes of mortality and disability
in the Western world. It is well established that carotid
atherosclerosis signiﬁcantly predisposes to cerebral ischemic
events, and mounting evidence correlates carotid plaque
texture with its stability.1 Nowadays, a family of b-galacto-
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//dx.doi.org/10.1016/j.ejvs.2014.10.009speciﬁc oligosaccharide structures or ligand glycoproteins or
glycolipids on the membranes of neighboring cells or in the
extracellular matrix (ECM).2 Galectin-3, a prominent member
of that family has been reported to propagate vascular
inﬂammation by inducing the expression of pro-
inﬂammatory mediators in macrophages and the migration
of monocytes into vascular walls.3 Despite the known
interplay between atherosclerosis and inﬂammation, the
contributory role of galectin-3 in atherogenesis progression
is still controversial.4,5 Moreover, limited evidence disputes
the potential role of galectin-3 in plaque destabilization.6,7
The primary aim of this study was to investigate the
relationship between galectin-3 and ipsilateral neurological
symptoms and ultrasound index of carotid plaque
Galectin-3, Carotid Plaque Vulnerability, and Potential Effects of Statin Therapy 5vulnerability. The hypothesis that long-term statin therapy
could favorably change concentrations of galectin-3 within
atherosclerotic plaques excised from patients undergoing
carotid endarterectomy (CEA) was also tested.
METHODS
Patients selection
Seventy eight consecutive patients with high grade carotid
stenosis, undergone CEA in the Department of Vascular
Surgery, “Attikon” University General Hospital, were
enrolled from January 2012 to October 2013. Written
informed consent from each patient was obtained before
enrollment and all procedures were performed according to
the principles of Helsinki Declaration and were approved by
the hospital human ethics committee.
Enrolled patients were assigned into either the symp-
tomatic group (SG) with at least intermediate stenosis
(>50%) or the asymptomatic group (AG) who had high
grade (>70%) stenosis of the internal carotid artery (ICA).
Patients with cerebral hemorrhage, severe liver or renal
impairment, heart failure (NYHA I-IV) and disorders
commonly associated with probable sources of car-
dioembolism, such as atrial ﬁbrillation and cardiac valve
abnormalities were excluded. Patients with concurrent
conditions/diseases interfering with the expression of in-
ﬂammatory mediators, like major trauma, surgery, cardio-
vascular ischemic events within the recent 1 month,
malignancies, chronic inﬂammatory, autoimmune diseases,
and patients with acute infection at the time of enrolment
were also ineligible.Clinical examination
Clinical parameters, such as body mass index (BMI), waist
hip ratio (WHR), and blood pressure (BP) were obtained. In
particular, the BMI was calculated using the following
equation: BMI ¼ weight (kg)/height (m)2. Waist circumfer-
ence was assessed midway between the lower rib margin
and the iliac crest. The hips were measured at the level of
the greater trochanter. Thus, WHR expressed waist circum-
ference divided by hip girth. BP was measured twice after
15 minutes rest in a sitting position, and the mean value
was estimated. The percentage of body fat mass was also
measured using the body composition analyzer (Bodystat
1500, Bodystat Ltd, Isle of Man, British Isles).
Moreover, current medications and co-morbidities,
including hypertension (blood pressure 140/90 mmHg or
use of antihypertensive agents), smoking status, diabetes
(fasting plasma glucose [FPG] 126 mg/dL or use of anti-
diabetic medications) and established coronary artery dis-
ease (history of myocardial infarction or percutaneous
coronary intervention or coronary artery bypass) were
documented through a structured questionnaire.Carotid ultrasound examination
Carotid ultrasound examinations were performed by two
experienced operators, with the use of a linear array12 MHz ultrasound transducer (General Electric LogiqE,
Riverside, CA, USA). Peak systolic velocity (PSV) and ICA/
common carotid artery PSV ratio were calculated and
thereafter the percentage of arterial stenosis was graded
according to the recommendations of the Society of Radi-
ologists in Ultrasound.8
Ultrasound image driven characterization of carotid pla-
que vulnerability and gray scale median (GSM) evaluation
has been in a spotlight of extensive investigation for de-
cades.9 In this study, the GSM score was estimated from
digitized B-mode ultrasound image recordings of a longi-
tudinal section of the carotid artery. Speciﬁcally, for each
patient, images were recorded at a minimal depth (4 cm)
without magniﬁcation (zoom). The recorded images were
assessed to identify the one with the best quality, which
was, then, transferred to a computer. A GSM measurement
of the plaque area was automatically obtained using in
house software developed in Matlab (version 2012b;
MathWorks, Natick, USA),10 which estimates the GSM score
following a standardized approach proposed by Elatrozy
et al.11 and has been commonly used by the scientiﬁc
community. The technicians doing the image analyses were
unaware of the clinical status of participants. For symp-
tomatic patients, the GSM score of the culprit lesion, ipsi-
lateral to the brain infarct was recorded, whereas in
asymptomatic patients the average value of GSM of all
plaques causing stenosis greater than 50% in both carotids
was considered.Histopathological analysis of carotid plaques
Surgically removed carotid plaques were collected for his-
topathological analysis. Plaques were ﬁxed in 10% neutral
buffered formalin and were sectioned in 0.5 cm blocks. All
sections of the plague were embedded in a single parafﬁn
block in order for a single section to contain the whole
length of the plague, including areas of maximum stenosis
and sites at equal intervals across the whole plaque length.
Three consecutive 3 mm sections were used for antibody
staining.12 Immunohistochemistry was performed on an
automated sample carrier (BondMax, Leica Biosystems,
Wetzlar, Germany). Primary antibodies against CD68 (clone
PGM-1, 1:100, Thermo Scientiﬁc, MI, USA), galectin-3 (clone
9C4, 1:150, Leica Biosystems, Newcastle, UK), and laminin
(clone 4C7, 1:30, Dako, Glostrup, Denmark) were incubated
after citrate pre-treatment. A commercially available
horseradish peroxidase/diaminobenzidine (DAB) detection
system (Bond Polymere Reﬁne, Leica Biosystems) was
used.13 Instead of subjectively selecting areas to measure
staining, the entire slide was scanned using PathSight
(Fairﬁeld Imaging) on a Leica DMBL microscope. The posi-
tivity percentage of each marker was measured using
ImagePro Plus as the percentage of positive stained area to
the whole hematoxylin stained area. Selection of the
stained area was based on automated color selection of
brown for DAB positive cells, cyan blue for hematoxylin
positive DAB negative cells, subtracting areas of background
staining, and artifacts caused by folding of parafﬁn sections.
Table 1. Clinical and carotid ultrasound parameters of
symptomatic and asymptomatic patients undergoing carotid
endarterectomy.
Symptomatic
patients
(n ¼ 40)
Asymptomatic
patients
(n ¼ 38)
p
Men/women 27/13 28/10 .585
Age (years) 69  9 72  9 .738
Smokers, n 14 (35%) 16 (42.1%) .320
Diabetes, n 12 (30%) 10 (26.3%) .569
Hypertension, n 34 (87.5%) 32 (84.2%) .701
CAD, n 16 (40%) 17 (44.7%) .851
BMI (kg/m2) 29.72  4.65 29.05  4.47 .712
Fat mass (%) 39.91  5.89 38.45  7.02 .398
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Fasting blood samples for FPG were obtained between 8:00
and 10:00 a.m. and lipid parameters were all measured in
an automatic enzymatic analyzer (Olympus AU560,
Hamburg, Germany). For multiplex bead based assays,
serum and plasma were collected after a centrifugation at
2,500 rpm for 10 minutes and frozen at 80 C until
analysis. Levels of galectin-3 were measured in serum, while
levels of high sensitivity C-reactive protein (hsCRP) were
measured in plasma. Bead assays were performed accord-
ing to the manufacturer’s protocol (MilliPore, Billerica, MA,
USA) and were analyzed on a Luminex 200 platform
(Luminex Corp, Austin, TX, USA).WHR 0.941  0.077 0.930  0.071 .492
SBP (mmHg) 139  16 135  16 .501
DBP (mmHg) 85  10 82  7 .293
Carotid stenosis (%) 83.9  9.8 87.2  10.5 .789
GSM score 44.21  18.24 68.79  28.79 <.001
Note. Data are means  SD. n, number of patients. BMI ¼ body
mass index; DBP, diastolic blood pressure; GSM ¼ grayscale
median; SBP ¼ systolic blood pressure; WHR ¼ waist hip ratio.
A two tailed p < .05 was considered to be statistically signiﬁcant.Statistical analysis
Normality of distribution was assessed with Kolmogorove
Smirnov test. Results of normally distributed continuous
variables are expressed as the mean value  SD. Contin-
uous and categorical variables were compared using the
Student t test and chi-square test, respectively. A two tailed
p-value <.05 was considered to be statistically signiﬁcant.
Pearson’s correlation coefﬁcient was calculated to deter-
mine the strength of the association between the contin-
uous characteristics. Variables showing a signiﬁcant
correlation with galectin-3 were then entered in a standard
multiple linear regression analysis after adjustment for age,
to check for independent associations. Logistic multiple
regression analysis was also performed to ﬁnd the inde-
pendent determinants of symptoms. Owing to the low
number of patients for many comparisons, a type I error
was avoided by selecting a lower signiﬁcance level for
multiple regression tests, for example, by rejecting the null
hypothesis when p < .01 instead of p < .05. The computer
software package SPSS (version 20.0; SPSS Inc, Chicago, IL,
USA) was used for statistical analysis.Table 2. Values of biochemical and immunohistochemical variables
in symptomatic and asymptomatic patients undergoing carotid
endarterectomy.
Symptomatic
patients
(n ¼ 40)
Asymptomatic
patients
(n ¼ 38)
p
TChol (mg/dL) 162.43  35 166.13  43.4 .936
HDL-C (mg/dL) 49.95  14.63 41.13  8.76 .138
LDL-C (mg/dL) 89.05  29.73 103.40  40.17 .919
TG (mg/dL) 109.95  62.58 151.00  76.16 .358
FPG (mg/dL) 142  45 144  47 .801
hsCRP (mg/L) 5.33  1.23 3.96  0.63 .002
WBC (cells/mL) 7705  2399 7729  1631 .069
Serum galectin-3
(ng/mL)
2.99  2.47 4.43  3.32 .601
Galectin-3 (%) 4.89  1.60 12.01  5.91 <.0001
Laminin (%) 0.88  0.71 3.46  2.12 <.0001
CD68 (%) 13.81  8.03 9  5.71 .003
Note. Data are means  SD. TChol ¼ total cholesterol;
TG ¼ triglycerides; hsCRP ¼ high sensitivity C reactive protein;
WBC ¼ white blood cells count; %, positive stained area
expressed as percentage of the total plaque size.RESULTS
Seventy eight patients with signiﬁcant ICA stenosis were
included in the study. Forty were symptomatic having suf-
fered an ipsilateral ischemic stroke (n ¼ 17), transient
ischemic attack (n ¼ 20) or amaurosis fugax (n ¼ 3). The
median time interval between the onset of neurological
symptoms and surgery was 20 (interquartile range: 7e32)
days. Patient demographics and co-morbidities are pre-
sented in Table 1. All participants were receiving statins for
at least 1 week prior to CEA and were on an antiplatelet
regimen (71 patients were on aspirin, 4 patients on clopi-
dogrel due to aspirin intolerance and 3 patients on a dual
antiplatelet regimen due to previous percutaneous coro-
nary intervention). Symptomatic and asymptomatic pa-
tients did not signiﬁcantly differ in the distribution of
gender, diabetes, hypertension, and smoking habits
(p > .05). Similarly, there was also no signiﬁcant difference
in age, BMI, fat mass, WHR, and the degree of carotid
stenosis (p > .05). However, SG had a lower GSM score
(p < .001) (Table 1) than AG.As shown in Table 2, there were no signiﬁcant differences
in glycemic and lipid parameters between groups (p > .05).
On the other hand, there were signiﬁcantly higher levels of
hsCRP in the SG than the AG group (p ¼ .002). The intra-
plaque analysis showed a signiﬁcantly higher content of
macrophages (p ¼ .003) within plaques obtained from
symptomatic than asymptomatic patients. Conversely, SG
had a smaller positive stained area for laminin (p < .001)
and galectin-3 (p < .001) (Table 2 and Fig. 1).
Among symptomatic patients, subgroup analysis of pa-
tients already receiving long term statin therapy (>1
month) (n ¼ 24) and those on short-term treatment (7e15
days preoperatively) (n ¼ 16) was performed. Long term
Figure 1. Representative histological sections of the human carotid plaques at the level of maximum stenosis of each lesion stained with
galectin-3. (A) Symptomatic group; (B) asymptomatic group.
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increased galectin-3 (5.85  2.02% vs. 3.33  1.12%,
p ¼ .039) and decreased relative macrophage
(11.89  5.15% vs. 17.22  5.15%, p < .001) concentra-
tions. Following similar analyses in the asymptomatic group,
a signiﬁcantly higher intra-plaque concentration of galectin-
3 was observed in long-term (>1 month) statin-treated
patients (n ¼ 26) than in those receiving statins in the
short term (7e15 days preoperatively) (n ¼ 12)
(13.1  6.08% vs. 9.61  4.28%, p ¼ .046). With the
exception of lower total cholesterol, low-density lipopro-
tein, and hsCRP circulating levels in the long term statin
subgroups, the rest of variables did not differ between the
above mentioned subgroups (p > .05) (data not shown).
Correlations
Correlations of both immunohistochemical and serum
values of galectin-3, with the rest of the variables in human
sample cohort were sought. In univariate analysis, carotid
plaque galectin-3 content was signiﬁcantly correlated with
GSM score (p < .001), laminin (p < .001), and female
gender (p ¼ .043). In multivariate analysis, GSM score
remained an independent determinant of galectin-3 con-
centrations (Table 3). Conversely serum galectin-3 levels
signiﬁcantly correlated with diabetes and hsCRP in univari-
ate analysis. However, only diabetes showed independent
correlation in multiple linear regression analysis (Table 4).
Finally, the authors investigated the independent de-
terminants of ipsilateral cerebrovascular events. In singleTable 3. Standard multiple regression analysis of carotid plaque
galectin-3 content (dependent variable) and other independent
variables, after adjustment for age.
Carotid plaque galectin-3 content
b 95% CI p
GSM score 0.620 0.487 to 0.761 <.001
Laminin 0.401 0.101 to 0.689 .069
Female gender 0.132 0.011 to 0.291 .149
Age 0.339 0.172 to 0.558 .455
Note. Because of the small number of patients statistical
signiﬁcance was deﬁned as p < .01. CI ¼ conﬁdence interval;
GSM ¼ grayscale median score.logistic regression analysis, age, history of CAD, serum
hsCRP, low HDL, and GSM score, as well as intra-plaque
contents of macrophages and galectin-3 were signiﬁcantly
associated with neurological symptoms in the whole study
group (p < .05). After entering the latter variables into the
multiple logistic regression analysis model, the independent
association of ipsilateral cerebrovascular events with intra-
plaque low content of galectin-3 (OR ¼ 0.634, p < .001)
and low GSM score (OR ¼ 0.750, p < .001) was observed.
DISCUSSION
The current study demonstrated lower content of galectin-3
in symptomatic versus asymptomatic carotid plaques. Most
importantly, the incidence of cerebrovascular events was
independently determined by low levels of intra-plaque
galectin-3 and a low GSM score. Long term, pre-operative
therapy with statins was associated with higher intra-
plaque galectin-3 levels than short term therapy.
The majority of animal studies have consistently indi-
cated the correlation between galectin-3 and atheroscle-
rosis development and its co-localization with
inﬂammatory cells within atherosclerotic lesions.14 Con-
trary to the proposed pro-atherogenic/pro-inﬂammatory
action of galectin-3, Iacobini et al.4 demonstrated the
opposite effects of galectin-3, since in its genetically
depleted mice there were more extensive and complex
atherosclerotic lesions than in wild type mice. The poten-
tial contradictory actions of galectin-3 have been also
outlined by two recent histopathological studies in human
carotid plaques. The ﬁrst one examined 21 carotid plaquesTable 4. Standard multiple regression analysis of serum galectin-3
levels (dependent variable) and other independent variables, after
adjustment for age.
Serum galectin-3 levels
b 95% CI p
Diabetes 0.626 0.514 to 0.771 <.001
hsCRP 0.316 0.205 to 0.503 .041
Age 0.192 0.023 to 0.306 .344
Note. Because of the small number of patients statistical
signiﬁcance was deﬁned as p < .01. CI ¼ conﬁdence interval;
GSM ¼ gray-scale median score.
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expression and protein levels in unstable rather than sta-
ble regions in the same patient.7 In contrast, a second
study questioned the positive interplay between galectin-3
and carotid plaque instability, implicating a dual role.15 In
particular, galectin-3 was not only expressed by inﬂam-
matory cells inﬁltrating unstable regions, but it was also
highly expressed in macro-calciﬁed, stable regions, pre-
dominantly occupied by VSMCs. Those authors hypothe-
sized galectin-3 to modulate inﬂammation and
osteogenesis in divergent ways.
To the authors’ knowledge this is the ﬁrst study evalu-
ating galectin-3 in human carotid plaques in relation to
clinical criteria of plaque vulnerability. The symptomatic
group had lower average protein concentrations of galectin-
3 than the asymptomatic group. Besides this, intra-plaque
galectin-3 was positively associated with GSM score. In
addition to macrophages, VSMCs may be important cellular
sources of galectin-3 within atherosclerotic plaques.16 Thus,
a possible explanation may derive from the limited calciﬁ-
cation and less ﬁbrous tissue accumulation, which pre-
dominantly characterizes vulnerable atherosclerotic
lesions.17 Unfortunately, in the current study the magnitude
of the intra-plaque calciﬁcation, ECM, and vascular smooth
muscle cells (VSMCs) was not examined, so it was hypoth-
esized that softer symptomatic plaques are poor in VSMC
content, leading to less galectin-3 expression. Another
plausible explanation may be attributed to the dual (pro-
inﬂammatory and anti-inﬂammatory) role of galectin-3
within symptomatic plaques. Perhaps, large macrophage
rich areas show increased galectin-3 production, while the
compensatory anti-inﬂammatory action of galectin-3 may
be excessively impaired in the rest of the non-inﬂamed
regions of the same plaque.18 Future studies searching
underlying pathways are required to clarify the precise pro-
atherogenic or anti-atherogenic actions of galectin-3 and
their regulators.
It is still the subject of debate to assume that athero-
sclerosis related agents, like galectin-3, could enter the
circulation and reﬂect ongoing activity within atheroscle-
rotic plaques.19 Accordingly, serum galectin-3 levels in this
study did not correlate with its respective concentration
within carotid plaques, implying that circulating galectin-3
may be not a marker of carotid plaque vulnerability.
Limited data have previously documented the relationship
between coronary plaque destabilization and plasma levels
of galectin-3.6 In the present study, all symptomatic patients
underwent CEA at least 1 month after the acute cerebro-
vascular event and all of them were on statin treatment for
adequate time. Those conditions might have blunted the
prognostic power of circulating galectin-3.
Another important ﬁnding of the present study was the
upregulation of galectin-3 in the small subgroup of symp-
tomatic patients already treated with long term statins. This
is the ﬁrst study reporting pharmaceutical modiﬁcation of
galectin-3 in atherosclerotic conditions. It is well known that
chronic statin treatment mediates carotid plaque stabiliza-
tion through the induction of plaque calciﬁcation and theshrinkage of inﬂammatory cells inﬁltration.20 Concerning
the dual role of galectin-3 with a prevalent anti-
inﬂammatory activity, this may corroborate the statin
related galectin-3 upregulation. Perhaps, this is an emerging
novel action within statins’ spectrum. On the other hand,
the opposite effect of statin administration on galectin-3
using atherosclerosis-prone mice was observed.7,21 In
particular, atorvastatin treatment markedly reduced intra-
plaque concentrations of galectin-3 accompanied with pla-
que regression and plaque stabilization. Firstly, species dif-
ferences may explain the divergent effects of statins on
galectin-3. Secondly, the impact of statins on advanced
atherosclerotic lesions was examined, and no ﬁrm conclu-
sions about the action of galectin-3 (pro-inﬂammatory
versus anti-inﬂammatory) during atherosclerosis evolution
in rodents could be drawn. More studies, in larger cohorts,
are required to unravel the response of galectin-3 to
pharmaceutical modiﬁcation.
Several drawbacks should be considered in the present
study. Firstly the regional distribution of galectin-3 was not
focused on, as previous researchers have reported.
Although doing so might have shed more light on cellular
sources, those histological indices with spatial distribution
do not necessarily reﬂect plaque rupture or erosion.
Perhaps the use of other indices of plaque instability, like
ﬁbrous cap thickness and ECM and VSMC content, would
have provided more ﬁrm evidence. Representative seg-
ments of each whole plaque were examined. However, the
concomitant histological assessment of plaque instability
would have supported the ﬁndings. Another important
limitation was the absence of assays of galectin-3 expres-
sion within plaques. That laboratory approach would pro-
vide a more precise estimation of its activity. Given the
relatively small sample size, these results, and especially
those derived from multiple regression analyses, should be
viewed as preliminary. Moreover, this study did not pro-
spectively address the potential clinical impact of modifying
galectin-3. A future pharmacodynamic study will provide a
rationale, along with results from other trials, for studying
the effects of statins on plaque stability in larger trials of
longer duration.
Despite the limitations discussed above, the ﬁndings
support the hypothesis that galectin-3 is predominantly an
anti-inﬂammatory mediator in advanced carotid plaques.
Thereby, low intra-plaque concentrations of galectin-3 are
more likely to represent suppressed anti-inﬂammatory
mechanisms and may subsequently contribute to plaque
vulnerability. The beneﬁcial effect of galectin-3 could be
enhanced by long term statin therapy. However, the latter
remains to be veriﬁed by further studies.
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